Figure 3.
CSF t-tau biomarker concentrations and their diagnostic performance across the Alzheimer’s disease continuum. (A) Box plots presenting CSF concentrations of Innotest t-tau, in-house MR, NTA and NTB t-tau in clinical cohort 1, including subjects across the Alzheimer’s disease continuum. (B) AUC with 95% CI from ROC analysis showing the diagnostic accuracies of all studied CSF biomarkers to distinguish between neurological control and amyloid-positive (Aβ+) cases of MCI; (C) amyloid-negative (Aβ−) and Aβ+ cases of MCI; and (D) Alzheimer’s disease (AD) and non-Alzheimer’s disease dementia cases (including alcohol-related dementia, vascular dementia, mixed dementia and unspecified dementia). (E) Correlation matrix presenting Spearman’s correlations for all measured t-tau and p-tau assays with each other and with CSF Aβ1-42 in the whole cohort. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns = non-significant.